
Danish biotech and contract research firm Gubra has signed a new agreement with German pharmaceutical giant Boehringer Ingelheim on the development of peptide compounds for treating obesity, according to a joint press announcement from the companies.
Thus, the two firms continue the collaboration between them which has been going on since 2017. Neither party wishes to disclose the financial terms behind the new deal, but the company's two former deals had lucrative potentials.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app